Comparative study between H. Pylori induced and NSAIDs induced peptic ulcer
Abstract
The use of Non-steroidal anti-inflammatory drugs as well as the infecting agent H Pylori has been attributed as the prominent common etiological factor for peptic ulcers in patients. Distinguishing proof of Helicobacter pylori as the essential etiologic factor in the improvement of peptic ulcer illness and the perception that the frequency of H. pylori increments with age have brought up the issue of a potential synergistic connection between the presence of H. pylori contamination and NSAID use in the improvement of treatment in gastroenterology. Both H.Pylori and NSAIDs have, nevertheless, been appeared to affect the creation rate and the nature of gastric cyclic AMP, the bodily fluid layer, mucosal prostaglandins, blood stream, and platelet-activating factor. Therefore, it is necessary to determine the risk factors such as age and history of peptic ulcers of the patient prior to prescribing. A co-prescription may be important to reduce the risk of peptic ulcers in patients of high risk. Since H.Pylori infection remains the world's most common chronic bacterial infection, it has been suggested that the establishment of a synergistic or additive effect of H.Pylori infection and NSAID use in the development of peptic ulcer is of great clinical importance as eradication of the bacterium is likely to reduce the risk of upper gastrointestinal complications in infected NSAID users. The prevention and overcoming of NSAIDS induced peptic ulcer and H Pylori induced peptic ulcer is embedded in the thorough understanding and assessment of pathophysiology and other underlying causes in each individual patient. There are wide range of studies that emphasize on the various methods of overcoming these conditions as well as understanding the co factors for the risk of ulcer. The main aim of the treatment is to protect the gastric mucosal layer from further eroding away and heal the mucosal ulcer as soon as possible to avoid further complications.
Full text article
References
2. Sipponen P, Hyvärinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scandinavian Journal of Gastroenterology. 1993 Jan 1;28(sup196):3-6. DOI: 10.3109/00365529309098333
3. Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Australian prescriber. 2017 Jun;40(3):91. doi: 10.18773/austprescr.2017.037
4. Robinson DR. Regulation of prostaglandin synthesis by antiinflammatory drugs. J Rheumatol Suppl 1997;47:32-9. https://pubmed.ncbi.nlm.nih.gov/9035018/
5. Cekin AH, Taskoparan M, Duman A, Sezer C, Cekin Y, Yolcular BO, Can H, Pehlivan FS, Cayirci M. The role of Helicobacter pylori and NSAIDs in the pathogenesis of uncomplicated duodenal ulcer. Gastroenterology Research and Practice. 2012 Jan 1;2012 doi: 10.1155/2012/189373
6. Marshall, B. J., J. A. Armstrong, D. B. McGechie, and R. J. Glancy. 1985. Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med. J. Austr. 142:436–439. DOI: 10.5694/j.1326-5377.1985.tb113443.x
7. Tytgat GN. Etiopathogenetic principles and peptic ulcer disease classification. Digestive diseases. 2011;29(5):454-8. DOI: 10.1159/000331520
8. Taha AS, Russell RI. Helicobacter pylori and non-steroidal anti-inflammatory drugs: uncomfortable partners in peptic ulcer disease. Gut. 1993 May;34(5):580.doi: 10.1136/gut.34.5.580
9. Kim JG, Graham DY, the Misoprostol Study Group. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol. 1994;89:203–207 https://pubmed.ncbi.nlm.nih.gov/8304304/
10. Hawkey GM, Everitt S, Pearson GM, et al. Non-steroidal anti-inflammatory drugs and Helicobacter pylori as independent risk factors for peptic ulcer bleeding. (Abstr.) Gastroenterology. 1997;112(suppl):A144 doi: 10.1155/2006/175217
11. Bianchi Porro G, Parente F, Imbesi V, et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: response to omeprazole dual therapy. Gut. 1996;39:22–26.DOI: 10.1136/gut.39.1.22
12. Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. World journal of gastroenterology: WJG. 2014 Jul 28;20(28):9439. doi: 10.3748/wjg.v20.i28.9439
13. Chan FK. HELICOBACTER PYLORIAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS. Gastroenterology Clinics. 2001 Dec 1;30(4):937-52. doi: 10.1016/s0889-8553(05)70221-1.
14. Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Missouri medicine. 2018 May;115(3):219. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140150/
15. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, 2017 Jan;66(1):6-30.Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM., European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. doi: 10.1136/gutjnl-2016-312288.
16. Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017 Jan 15;11(1):27-37. doi: 10.5009/gnl15502
17. Sachdeva AK, Zaren HA, Sigel B. Surgical treatment of peptic ulcer disease. Med Clin North Am. 1991 Jul;75(4):999-1012. https://doi.org/10.1177/0003134820939929
18. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.Chey WD, Leontiadis GI, Howden CW, Moss SFAm J Gastroenterol. 2017 Feb; 112(2):212-239.
doi: 10.1038/ajg.2016.563
19. Dzieniszewski J, Jarosz M. Guidelines in the medical treatment of Helicobacter pylori infection. Journal of physiology and pharmacology: an official journal of the Polish Physiological Society. 2006 Sep 1;57:143-54. PMID: 17033112
20. Lanas AI, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology. 1995;109:1124–1133. https://doi.org/10.1016/0016-5085(95)90570-7
21. Lanas A, Chan FKL. Peptic ulcer disease. The Lancet. 2017;390:613–624. https://doi.org/10.1016/S0140-6736(16)32404-7